FDA approves label update for LHRH treatment for prostate Ca
TOLMAR Pharmaceuticals has announced that it received FDA approval for a label update for leuprolide acetate for injectable suspension (Eligard), a luteinizing hormone-releasing hormone (LHRH) agonist. Prior to mixing, the drug may be stored for up 8 weeks at room temperature (59–86° F) following removal from refrigeration, according to the FDA. Eligard, indicated for the palliative treatment of advanced prostate cancer, uses a controlled-release delivery system known as ATRIGEL. It is available in 1-, 3-, 4-, and 6-months doses.
For more information, visit www.tolmar.com.